S&P 500 7,628.29 â–ŧ 57.85 (-0.75%) DOW 52,759.94 â–ŧ 425.96 (-0.80%) NASDAQ 26,096.35 â–ŧ 274.54 (-1.04%) US Markets Closed â€ĸ 07:29 PM ET

GRFS

Grifols, S.A.

Price Chart

No historical data available

Latest Quote

$7.69

-0.13 (-1.66%)
Current Price
Previous Close $7.82
Open $7.83
Day High $7.88
Day Low $7.68
Volume 322,332
Fetched: 2026-08-31T08:37:53
Stock Information
Note: Financial values converted from EUR to USD
Quarterly Dividend / Yield $0.28 / 3.66%
Shares Outstanding 258.22M
Quarterly Dividend Yield 3.66%
Quarterly Dividend $0.28
Total Debt $10.86B
Cash Equivalents $623.04M
Revenue $8.61B
Net Income $524.42M
Sector Healthcare
Industry Drug Manufacturers - General
Market Cap $5.23B
P/E Ratio 9.99
EPS (TTM) $0.77
Exchange NMS
🌐 Visit Website
Recent Price History
No history data available. Data will be fetched automatically.
About Grifols, S.A.

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

📰 Latest News
No news articles available at the moment. Check back later for updates on GRFS.
Period:
Loading...
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Reconciled Cost Of Revenue $5,029,585,779 $4,747,650,521 $4,374,057,298 $4,092,509,556
Cost Of Revenue $5,412,460,821 $5,125,884,653 $4,767,374,387 $4,467,173,668
Total Revenue $8,729,550,958 $8,367,560,009 $7,648,219,021 $7,035,580,666
Operating Revenue $8,447,615,699 $8,126,232,710 $7,411,532,631 $6,745,332,379
Expenses
Interest Expense $668,290,982 $698,456,895 $598,677,338 $515,770,969
Total Expenses $7,278,106,480 $7,027,497,362 $6,815,175,748 $6,247,834,991
Other Income Expense $-35,967,049 $-11,602,274 $55,690,915 $141,222,879
Net Non Operating Interest Income Expense $-701,937,577 $-813,319,407 $-649,727,344 $-536,796,610
Total Other Finance Cost $73,094,326 $165,912,518 $122,984,104 $60,309,780
Interest Expense Non Operating $668,290,982 $698,456,895 $598,677,338 $515,770,969
Operating Expense $1,865,645,659 $1,901,612,709 $2,047,801,361 $1,780,661,323
Other Operating Expenses $-1,160,227 - $-3,480,682 $-25,797,656
General And Administrative Expense $1,233,321,726 $1,326,139,918 $1,468,847,888 $1,285,288,311
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $466,411,415 $182,155,702 $48,729,551 $214,682,677
Net Interest Income $-701,937,577 $-813,319,407 $-649,727,344 $-536,796,610
Interest Income $39,447,732 $51,050,006 $71,934,099 $39,284,140
Normalized Income $488,106,507 $223,053,718 $62,500,211 $197,899,092
Net Income From Continuing And Discontinued Operation $466,411,415 $182,155,702 $48,729,551 $214,682,677
Total Operating Income As Reported $1,442,162,658 $1,382,991,061 $907,297,827 $907,803,686
Net Income Common Stockholders $466,411,415 $182,155,702 $48,729,551 $214,682,677
Net Income $466,411,415 $182,155,702 $48,729,551 $214,682,677
Net Income Including Noncontrolling Interests $580,113,700 $247,128,436 $189,117,066 $287,622,693
Net Income Continuous Operations $580,113,700 $247,128,436 $189,117,066 $287,622,693
Pretax Income $713,539,851 $515,140,966 $239,006,844 $392,171,944
Special Income Charges $-3,480,682 $-10,442,047 $0 $0
Earnings From Equity Interest $-9,281,819 $42,928,414 $73,094,326 $118,338,554
Interest Income Non Operating $39,447,732 $51,050,006 $71,934,099 $39,284,140
Operating Income $1,451,444,477 $1,340,062,647 $833,043,273 $787,745,675
Depreciation Amortization Depletion Income Statement $139,227,288 $129,945,469 $124,144,332 $102,166,144
Depreciation And Amortization In Income Statement $139,227,288 $129,945,469 $124,144,332 $102,166,144
Gross Profit $3,317,090,137 $3,241,675,356 $2,880,844,634 $2,568,406,998
Per Share
Diluted EPS $0.68 $0.27 $0.10 $0.36
Basic EPS $0.68 $0.27 $0.10 $0.36
Other
Tax Effect Of Unusual Items $-4,990,138 $-13,632,672 $-3,632,751 $6,100,740
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $1,930,618,394 $1,776,308,149 $1,372,549,014 $1,361,888,845
Total Unusual Items $-26,685,230 $-54,530,688 $-17,403,411 $22,884,325
Total Unusual Items Excluding Goodwill $-26,685,230 $-54,530,688 $-17,403,411 $22,884,325
Reconciled Depreciation $522,102,330 $508,179,601 $517,461,420 $476,830,257
EBITDA (Bullshit earnings) $1,903,933,163 $1,721,777,462 $1,355,145,603 $1,384,773,170
EBIT $1,381,830,833 $1,213,597,860 $837,684,183 $907,942,913
Diluted Average Shares $790,779,838 $788,858,002 $788,671,878 $788,728,552
Basic Average Shares $789,549,325 $788,570,076 $788,671,878 $788,728,552
Diluted NI Availto Com Stockholders $466,411,415 $182,155,702 $48,729,551 $214,682,677
Minority Interests $-113,702,285 $-64,972,734 $-140,387,515 $-72,940,016
Tax Provision $133,426,151 $268,012,529 $49,889,778 $104,549,251
Write Off $3,480,682 $10,442,047 $0 $0
Gain On Sale Of Security $-23,204,548 $-44,088,641 $-17,403,411 $22,884,325
Research And Development $494,256,872 $445,527,322 $458,289,823 $419,004,523
Selling General And Administration $1,233,321,726 $1,326,139,918 $1,468,847,888 $1,285,288,311
Other Gand A $1,233,321,726 $1,326,139,918 $1,468,847,888 $1,285,288,311
Gain On Sale Of Ppe - - $-28,997,563 $-21,117,299
Salaries And Wages - - $613,509,685 $548,106,507
Fetched: 2026-08-31
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $-4,977,375,546 $-5,158,371,020 $-4,949,468,596 $-5,003,518,950
Total Assets $22,870,402,509 $24,834,667,497 $24,355,613,084 $24,631,145,047
Total Non Current Assets $16,983,408,681 $18,188,884,950 $17,242,240,331 $19,188,838,537
Non Current Prepaid Assets $18,563,638 $10,442,047 $10,293,537 $10,763,430
Non Current Deferred Assets $482,654,598 $396,797,771 $348,449,935 $202,950,457
Non Current Deferred Taxes Assets $482,654,598 $396,797,771 $348,449,935 $202,950,457
Non Current Note Receivables $154,310,244 $23,204,548 $158,517,229 $127,273,465
Financial Assets $0 $1,160,227 $1,210,117 $31,360,947
Investmentin Financial Assets $421,162,546 $533,704,604 $34,962,292 $576,184,010
Financial Assets Designatedas Fair Value Through Profitor Loss Total $2,320,455 $5,801,137 $8,122 -
Goodwill And Other Intangible Assets $11,092,934,171 $11,983,988,815 $11,178,005,525 $11,557,090,104
Other Intangible Assets $3,165,100,347 $3,394,825,372 $3,285,991,401 $3,421,681,156
Current Assets $5,886,993,828 $6,645,782,547 $7,113,372,753 $5,442,306,511
Other Current Assets $75,414,781 $83,536,373 $85,789,534 $95,924,121
Hedging Assets Current $0 $6,961,364 $27,432,417 $14,652,512
Restricted Cash $27,845,458 $0 - -
Prepaid Assets $10,442,047 $11,602,274 $5,192,018 $22,499,130
Inventory $3,824,109,510 $4,130,409,544 $4,040,374,738 $3,754,507,469
Receivables $993,154,654 $1,251,885,365 $1,058,355,954 $898,245,733
Other Receivables $140,387,515 $61,492,052 $99,718,064 $125,693,235
Taxes Receivable $83,536,373 $124,144,332 $92,586,147 $65,880,032
Loans Receivable $13,922,729 $248,288,664 $117,573,964 $55,691
Accounts Receivable $755,308,037 $817,960,317 $748,477,779 $706,672,465
Allowance For Doubtful Accounts Receivable $-26,685,230 $-24,364,775 $-36,635,340 $-37,464,903
Gross Accounts Receivable $781,993,268 $842,325,092 $785,113,119 $743,681,399
Cash Cash Equivalents And Short Term Investments $956,027,378 $1,161,387,627 $631,747,300 $673,211,507
Cash And Cash Equivalents $929,342,147 $1,137,022,852 $614,429,746 $637,205,010
Cash Equivalents $9,281,819 $5,801,137 $7,548,439 $5,801
Cash Financial $920,060,328 $1,131,221,715 $606,881,306 $635,780,250
Other Non Current Assets - $158,951,154 $157,366,283 $144,089,801
Non Current Accounts Receivable - $68,453 - -
Assets Held For Sale Current - $0 $1,264,480,793 $5,765,170
Debt
Net Debt $8,914,027,114 $9,271,377,153 $10,827,297,788 $9,496,695,635
Total Debt $11,098,735,308 $11,733,379,696 $12,731,120,730 $11,312,362,178
Long Term Debt And Capital Lease Obligation $10,491,936,378 $10,958,347,793 $11,584,921,639 $10,521,930,577
Long Term Debt $9,367,676,028 $9,769,114,708 $10,419,789,958 $9,460,800,520
Current Debt And Capital Lease Obligation $606,798,930 $775,031,903 $1,146,199,091 $790,431,601
Current Debt $475,693,234 $639,285,297 $1,021,937,576 $671,675,366
Other Current Borrowings $475,693,234 $639,285,297 $1,021,937,576 $671,675,366
Liabilities
Total Liabilities Net Minority Interest $14,049,193,587 $14,849,750,493 $15,638,018,270 $15,377,021,636
Total Non Current Liabilities Net Minority Interest $11,706,694,466 $12,348,300,218 $12,939,975,584 $13,034,202,292
Other Non Current Liabilities $58,011,370 $54,530,688 $56,327,880 $11,688,328,066
Derivative Product Liabilities $1,160,227 $0 $12,763 $4,644,390
Non Current Deferred Liabilities $1,017,519,430 $1,190,393,312 $1,163,053,714 $1,218,176,118
Non Current Deferred Taxes Liabilities $998,955,791 $1,174,150,129 $1,147,034,454 $1,200,629,999
Current Liabilities $2,342,499,121 $2,501,450,274 $2,698,042,686 $2,342,819,343
Other Current Liabilities $92,818,192 $48,729,551 $49,633,368 $1,211,693,927
Current Deferred Liabilities $39,447,732 $49,889,778 $45,472,792 $43,896,043
Payables And Accrued Expenses $1,562,826,308 $1,582,550,174 $1,401,271,604 $1,065,759,365
Payables $1,562,826,308 $1,582,550,174 $1,401,271,604 $1,065,759,365
Other Payable $529,063,694 $494,256,872 $403,795,102 $133,341,454
Total Tax Payable $58,011,370 $99,779,556 $42,663,882 $18,200,487
Income Tax Payable $29,005,685 $70,773,871 $16,849,983 $18,200,487
Accounts Payable $975,751,243 $988,513,745 $954,812,620 $914,217,423
Equity
Common Stock Equity $6,115,558,625 $6,825,617,794 $6,228,536,929 $6,553,571,154
Total Equity Gross Minority Interest $8,821,208,922 $9,984,917,004 $8,717,594,814 $9,254,123,412
Stockholders Equity $6,115,558,625 $6,825,617,794 $6,228,536,929 $6,553,571,154
Gains Losses Not Affecting Retained Earnings $4,723,285,745 $5,603,898,342 $5,161,241,423 $5,546,363,825
Other Equity Adjustments $4,848,590,305 $4,693,119,833 $4,680,777,334 $4,692,695,190
Retained Earnings $348,068,220 $182,155,702 $49,098,503 $0
Long Term Equity Investment $112,542,058 $80,055,691 $489,340,989 $1,737,973,076
Other
Treasury Shares Number $8,097,919 $8,290,758 $9,818,574 $10,609,368
Ordinary Shares Number $789,622,125 $789,429,286 $787,901,469 $787,110,676
Share Issued $797,720,043 $797,720,043 $797,720,043 $797,720,043
Tangible Book Value $-4,977,375,546 $-5,158,371,020 $-4,949,468,596 $-5,003,518,950
Invested Capital $15,958,927,887 $17,234,017,800 $17,670,264,462 $6,553,571,154
Working Capital $3,544,494,707 $4,144,332,273 $4,415,330,067 $3,099,487,167
Capital Lease Obligations $1,255,366,047 $1,324,979,691 $1,289,393,196 $1,179,886,293
Total Capitalization $15,483,234,653 $16,594,732,502 $16,648,326,886 $6,553,571,154
Minority Interest $2,705,650,297 $3,159,299,210 $2,489,057,886 $2,700,552,258
Foreign Currency Translation Adjustments $-11,602,274 $931,662,602 $480,464,089 $853,668,636
Unrealized Gain Loss $-113,702,285 $-20,884,093 $0 $0
Treasury Stock $151,989,789 $156,630,699 $177,222,415 $188,212,089
Additional Paid In Capital $1,056,967,161 $1,056,967,161 $1,056,651,580 $1,056,651,580
Capital Stock $139,227,288 $139,227,288 $138,767,838 $138,767,838
Common Stock $139,227,288 $139,227,288 $138,767,838 $138,767,838
Non Current Deferred Revenue $18,563,638 $16,243,184 $16,019,260 $17,546,119
Long Term Capital Lease Obligation $1,124,260,351 $1,189,233,085 $1,165,131,681 $1,061,130,057
Long Term Provisions $138,067,061 $145,028,425 $135,659,589 $127,698,108
Current Deferred Revenue $39,447,732 $49,889,778 $45,472,792 $43,896,043
Current Capital Lease Obligation $131,105,696 $135,746,606 $124,261,515 $118,756,236
Current Provisions $40,607,959 $45,248,869 $55,465,831 $65,366,051
Investments And Advances $533,704,604 $613,760,295 $524,303,281 $2,314,157,086
Available For Sale Securities $418,842,091 $527,903,467 $34,954,171 $576,184,010
Goodwill $7,927,833,824 $8,589,163,442 $7,892,014,124 $8,135,408,948
Net PPE $4,701,241,425 $5,000,580,094 $4,864,094,423 $4,970,551,088
Accumulated Depreciation $-3,089,685,566 $-3,063,000,336 $-2,640,523,252 $-2,417,275,777
Gross PPE $7,790,926,991 $8,063,580,430 $7,504,617,676 $4,970,551,088
Leases $1,510,616,075 $1,537,301,305 $1,410,904,972 $1,293,252,112
Construction In Progress $842,325,092 $930,502,375 $1,056,584,286 $1,019,161,152
Machinery Furniture Equipment $4,035,270,897 $4,167,536,821 $3,723,853,101 $3,600,723,968
Land And Improvements $1,402,714,927 $1,428,239,929 $1,313,275,317 $1,340,533,699
Properties $0 $0 $0 $0
Inventories Adjustments Allowances $-114,862,513 $-174,034,110 - -
Finished Goods $1,220,559,225 $1,453,764,932 $1,369,083,415 $933,909,963
Work In Process $1,632,439,952 $1,714,816,097 $1,403,973,773 $1,545,009,856
Raw Materials $1,085,972,846 $1,135,862,625 $1,267,317,549 $1,235,382,290
Other Short Term Investments $26,685,230 $24,364,775 $17,317,554 $36,006,497
Employee Benefits - - $116,207,216 $109,143,752
Non Current Pension And Other Postretirement Benefit Plans - - $116,207,216 $109,143,752
Other Properties - - - $4,970,551,088
Fetched: 2026-08-31
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $723,981,898 $614,920,522 $-107,901,148 $-457,476,504
Operating Activities
Operating Cash Flow $1,214,758,088 $1,046,525,115 $251,769,346 $-1,655,644
Cash Flow From Continuing Operating Activities $1,214,758,088 $1,046,525,115 $251,769,346 $-1,655,644
Operating Gains Losses $11,602,274 $-41,768,186 $-64,972,734 $-120,346,908
Investing Activities
Capital Expenditure $-490,776,190 $-431,604,593 $-359,670,494 $-455,820,859
Investing Cash Flow $-671,771,665 $1,027,961,476 $-457,129,596 $-2,315,956,598
Cash Flow From Continuing Investing Activities $-671,771,665 $1,027,961,476 $-457,129,596 $-2,315,956,598
Net Other Investing Changes - $1,814,595,654 - $106,013,458
Financing Activities
Financing Cash Flow $-613,760,295 $-1,576,749,037 $199,559,113 $-191,322,658
Cash Flow From Continuing Financing Activities $-613,760,295 $-1,576,749,037 $199,559,113 $-191,322,658
Net Other Financing Charges $-327,184,127 $-1,446,803,568 $334,145,491 $-65,625,942
Cash Dividends Paid $-148,509,107 $-1,160,227 $0 $-686,855
Common Stock Dividend Paid $-148,509,107 $-1,160,227 $0 -
Repurchase Of Capital Stock - $0 $0 $-4,013,227
Net Common Stock Issuance - $0 $0 $-4,013,227
Other
Repayment Of Debt $-138,067,061 $-128,785,241 $-134,586,378 $-120,996,635
End Cash Position $957,187,605 $1,137,022,852 $613,760,295 $637,205,010
Beginning Cash Position $1,137,022,852 $613,760,295 $636,964,843 $3,104,892,667
Effect Of Exchange Rate Changes $-109,061,376 $25,525,003 $-17,403,411 $41,247,244
Changes In Cash $-70,773,871 $497,737,555 $-5,801,137 $-2,508,934,901
Net Issuance Payments Of Debt $-138,067,061 $-128,785,241 $-134,586,378 $-120,996,635
Net Long Term Debt Issuance $-138,067,061 $-128,785,241 $-134,586,378 $-120,996,635
Long Term Debt Payments $-138,067,061 $-128,785,241 $-134,586,378 $-120,996,635
Net Investment Purchase And Sale $-60,331,825 $-51,050,006 $-90,497,737 $-191,038,403
Sale Of Investment $5,801,137 $0 $17,403,411 $0
Purchase Of Investment $-66,132,962 $-51,050,006 $-107,901,148 $-191,038,403
Net Business Purchase And Sale $-125,304,559 $-331,825,036 $-33,646,595 $-1,778,934,904
Purchase Of Business $-125,304,559 $-331,825,036 $-33,646,595 $-1,778,934,904
Net Intangibles Purchase And Sale $-183,315,929 $-161,271,609 $-99,779,556 $-126,544,842
Purchase Of Intangibles $-183,315,929 $-161,271,609 $-99,779,556 $-126,544,842
Net PPE Purchase And Sale $-302,819,351 $-242,487,527 $-233,205,707 $-325,451,907
Sale Of PPE $4,640,910 $27,845,458 $26,685,230 $3,824,110
Purchase Of PPE $-307,460,261 $-270,332,984 $-259,890,938 $-329,276,017
Taxes Refund Paid $-196,078,431 $-204,200,022 $-184,476,157 $-227,910,430
Interest Received Cfo $11,602,274 $12,762,501 $16,243,184 $4,703,562
Interest Paid Cfo $-617,240,977 $-662,489,845 $-613,760,295 $-406,528,598
Change In Working Capital $-35,967,049 $26,685,230 $-421,162,546 $-677,980,041
Change In Other Current Assets $4,640,910 $11,602,274 $15,082,956 $-2,612,832
Change In Payables And Accrued Expense $109,061,376 $33,646,595 $120,663,650 $146,788,490
Change In Payable $109,061,376 $33,646,595 $120,663,650 $146,788,490
Change In Inventory $-112,542,058 $30,165,912 $-476,853,461 $-732,245,037
Change In Receivables $-37,127,277 $-48,729,551 $-80,055,691 $-89,910,662
Other Non Cash Items $748,346,673 $807,518,270 $646,246,662 $476,209,535
Asset Impairment Charge $56,851,143 $84,696,600 $117,182,967 $81,195,034
Depreciation Amortization Depletion $522,102,330 $508,179,601 $517,461,420 $476,830,257
Depreciation And Amortization $522,102,330 $508,179,601 $517,461,420 $476,830,257
Earnings Losses From Equity Investments $9,281,819 $-42,928,414 $-73,094,326 $-118,338,554
Gain Loss On Sale Of PPE $2,320,455 $1,160,227 $8,121,592 $-2,008,354
Net Income From Continuing Operations $713,539,851 $515,140,966 $239,006,844 $392,171,944
Common Stock Payments - $0 $0 $-4,013,227
Sale Of Business - - $0 $106,013,458
Fetched: 2026-08-31